Upcoming Biosimilars: With semaglutide's patent set to expire around 2032, several generic and biotech companies are preparing to introduce biosimilar versions
While this might sound appealing if youre tired, the trade-offs include anxiety, elevated heart rate, sleep problems, and potential for dependency
Caliendo didnt hyper-focus on the GLP-1 community when he built the dish, but several elements align with the eating preferences and limitations of these consumers
Injection guidance: Your provider will explain self-injection technique
Obesity and metabolic conditions are among the most urgent health challenges worldwide , affecting over one-third of adults and contributing to diabetes, heart disease, and fatty liver disease
Retatrutide is a triple hormone (GIP, GLP-1 and glucagon) receptor agonist in development for the treatment of obesity